Print

Pacira Pharmaceuticals, Inc. Launches EXPAREL┬« Pivotal Nerve Block Trial  
9/26/2012 8:53:07 AM

PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced initiation of its Phase 2/3 pivotal trial of EXPAREL® (bupivacaine liposome injectable suspension) administered as a single-dose injection femoral nerve block for total knee arthroplasty surgery. Results from this study and a forthcoming second trial focused on intercostal nerve block for thoracotomy will contribute to a planned U.S. Food and Drug Administration supplemental New Drug Application (sNDA) filing in late 2013 or early 2014.
//-->